TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3549399

Group type: EXPERIMENTAL
Intervention: New trivalent vaccine produced exclusively on human tissue
Number of subjects: 120

Group type: COMPARATOR
Intervention: Commercially available M-M-R-II vaccine produced by MSD
Number of subjects: 120
Study: 30502978

Group type: EXPERIMENTAL
Intervention: PCpIOL implantation (Visian ICL/TICL of V4C design)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SMILE procedure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 26820305

Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenates (BSH)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (alfalfa sprout homogenate, ASH)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus (LAIV)
Number of subjects: 29
Study: 24281139

Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 38
Study: 23051991

Group type: EXPERIMENTAL
Intervention: NA-1 (Tat-NR2B9c) intravenous infusion
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 185
Study: 20556417

Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 9
Study: 18705272

Group type: EXPERIMENTAL
Intervention: 50mg diacerein tablets administered twice daily for 12 weeks
Number of subjects: 7923
Study: 15815185

Group type: EXPERIMENTAL
Intervention: COH-BMT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: FACT-BMT
Number of subjects: 92

Group type: COMPARATOR
Intervention: MOS-SF-36
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: COH-BMT and FACT-BMT
Number of subjects: 92
Study: 14960007

Group type: EXPERIMENTAL
Intervention: 50% mandibular advancement
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 75% mandibular advancement
Number of subjects: 74
Study: 10767507

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted vaginal hysterectomy (LAVH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vaginally assisted laparoscopic hysterectomy (VALH)
Number of subjects: 70
Study: 8803363

Group type: EXPERIMENTAL
Intervention: Supportive intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 54
Study: 31791333

Group type: EXPERIMENTAL
Intervention: Vitamin D fortified foods (30 μg vitamin D3/day through fortified yoghurt, cheese, eggs, and crisp-bread)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Vitamin D fortified foods
Number of subjects: 143
Study: 30032193

Group type: EXPERIMENTAL
Intervention: E2 addback during aromatase inhibition
Number of subjects: 74
Study: 26163352

Group type: EXPERIMENTAL
Intervention: TTM‐tailored computerized intervention at baseline, 6 months, and 12 months
Number of subjects: 1894

Group type: EXPERIMENTAL
Intervention: TTM‐tailored computerized intervention
Number of subjects: 1894
Study: 25150151

Group type: EXPERIMENTAL
Intervention: MRI after 3 cycles and post-NAC
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 250
Study: 22216905

Group type: EXPERIMENTAL
Intervention: Online decision aid 'zelftestwijzer'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short, non-interactive information on self-testing
Number of subjects: 0
Study: 18937229

Group type: EXPERIMENTAL
Intervention: Axillary lymph node nanometastases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Literature data set on prostate cancer
Number of subjects: 0
Study: 16870959

Group type: EXPERIMENTAL
Intervention: Concomitant psychotropic medications (82% of patients)
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Anxiety or depression
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Better neurocognitive functioning
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Symptoms likely targets of polypharmacy (e.g., depression)
Number of subjects: 1380
Study: 12600855

Group type: EXPERIMENTAL
Intervention: 6 mg Cu/L water
Number of subjects: 1365

Group type: COMPARATOR
Intervention: <0.01 mg Cu/L water
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Copper intake
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Copper-load variables
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Liver function tests
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Superoxide dismutase activity
Number of subjects: 1365
Study: 10953652

Group type: EXPERIMENTAL
Intervention: Removable intraoral appliances that advance the mandible during sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy with continuous positive airway pressure (CPAP)
Number of subjects: 0
Study: 9365348

Group type: EXPERIMENTAL
Intervention: Local heat application over the right palm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (contralateral hand)
Number of subjects: 20
Study: 1399664

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30
Study: 3886068

Group type: EXPERIMENTAL
Intervention: 3 mm suction drain left in the gallbladder bed
Number of subjects: 155

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 155
Study: 29667233

Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Conventional sterile gauzes (CSG)
Number of subjects: 630

Group type: COMPARATOR
Intervention: TR Band
Number of subjects: 630
Study: 26916657

Group type: EXPERIMENTAL
Intervention: Group A (1.5 ml/s)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group B (2.0 ml/s)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group C (3.0 ml/s)
Number of subjects: 51
Study: 25318111

Group type: EXPERIMENTAL
Intervention: Long duration of intravenous (IV) antibiotics (125 hours)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ultrasound ordered (85%)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram (VCUG) ordered (61%)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Consult requested (54%)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Wait for VCUG (53 hours)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Born preterm (13%)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Known genitourinary disease (17%)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Younger age (4.2 weeks)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Shorter duration of IV antibiotics (62 hours)
Number of subjects: 142

Group type: COMPARATOR
Intervention: No VCUG ordered
Number of subjects: 142

Group type: COMPARATOR
Intervention: Transition to oral antibiotics
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed ordering of VCUG
Number of subjects: 142
Study: 22233325

Group type: EXPERIMENTAL
Intervention: Base-in prism treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (no prism)
Number of subjects: 29
Study: 19578229

Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg single dose (n=91)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ciprofloxacin 20 mg/kg single dose (n=89)
Number of subjects: 180
Study: 18081900

Group type: EXPERIMENTAL
Intervention: OAG patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 16846418

Group type: EXPERIMENTAL
Intervention: Internal cardioversion using Syncrus heart wires
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 174
Study: 12806460

Group type: EXPERIMENTAL
Intervention: Oral artemisinin (various doses for one day)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Primaquine (30mg daily for 7 days)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Primaquine (30mg daily for 5 days)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Chloroquine (single dose)
Number of subjects: 234
Study: 10746603

Group type: EXPERIMENTAL
Intervention: Pergolide (up to 300 microg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8634728

Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone sodium phosphate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2002231

Group type: EXPERIMENTAL
Intervention: Erythromycin base 250 mg b.i.d. for 18 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36
Study: 6405417

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg) taken at bedtime
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 29533717

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 37% carbamide peroxide (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions (35% hydrogen peroxide and 37% carbamide peroxide)
Number of subjects: 50
Study: 28030569

Group type: EXPERIMENTAL
Intervention: Culturally‐specific education programme (PACE and CDSMP)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 375
Study: 25270275

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold (transfusion at 7 g/dL or less)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Higher hemoglobin threshold (transfusion at 9 g/dL or less)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold
Number of subjects: 998

Group type: COMPARATOR
Intervention: Higher hemoglobin threshold
Number of subjects: 998
Study: 22124771

Group type: EXPERIMENTAL
Intervention: Sodium citrate catheter locks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline catheter locks
Number of subjects: 78
Study: 20623992

Group type: EXPERIMENTAL
Intervention: Panitumumab plus chemotherapy (intravenous panitumumab 6 mg/kg every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panitumumab plus oxaliplatin-based chemotherapy (FOLFOX4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panitumumab plus irinotecan-based chemotherapy (FOLFIRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panitumumab monotherapy plus best supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 0
Study: 19072526

Group type: EXPERIMENTAL
Intervention: Social intervention promoting sexual communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16152826

Group type: EXPERIMENTAL
Intervention: Ganshao Capsule (GSC) for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ganshao Capsule (GSC) followed by Clomiphene (CC) for ovulation induction
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clomiphene (CC) for ovulation induction after GSC
Number of subjects: 27
Study: 14660449

Group type: COMPARATOR
Intervention: Single drop of 2.5% povidone‐iodine ophthalmic solution at birth
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Double drop of 2.5% povidone‐iodine ophthalmic solution (one at birth, one at discharge)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Double drop group
Number of subjects: 719
Study: 10664920

Group type: EXPERIMENTAL
Intervention: Repaglinide (4 mg single dose)
Number of subjects: 24
Study: 8686956

Group type: EXPERIMENTAL
Intervention: Pravastatin (cholesterol lowering intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean segment diameter and minimum obstruction diameter (proposed endpoints for standardization)
Number of subjects: 0
Study: 1474075

Group type: EXPERIMENTAL
Intervention: Voluntary contraction
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nonvoluntary contraction
Number of subjects: 8
Study: 3881870

Group type: EXPERIMENTAL
Intervention: TUR plus BCG
Number of subjects: 86

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 86
Study: 31016447

Group type: EXPERIMENTAL
Intervention: iopromide 300 mg I/ml
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: iopromide 370 mg I/ml
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: iomeprol 400 mg I/ml
Number of subjects: 1024

Group type: COMPARATOR
Intervention: All contrast media
Number of subjects: 1024
Study: 30782918

Group type: EXPERIMENTAL
Intervention: Six-session group-based intervention
Number of subjects: 60
Study: 28366039

Group type: EXPERIMENTAL
Intervention: OTC 1% colloidal oatmeal cream
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prescription barrier cream
Number of subjects: 90
Study: 25626811

Group type: EXPERIMENTAL
Intervention: Eyelid cooling with an ice pack
Number of subjects: 38

Group type: COMPARATOR
Intervention: Uncooled eyelids
Number of subjects: 38
Study: 22963270

Group type: EXPERIMENTAL
Intervention: Yoga intervention (twice a week at 30 minutes/session for 8 weeks)
Number of subjects: 70
Study: 21788633

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 16
Study: 20084934

Group type: EXPERIMENTAL
Intervention: Galvanism penetration of traditional Chinese medicine, ultrasonic wave and manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasonic wave and manipulation
Number of subjects: 80
Study: 16400507

Group type: EXPERIMENTAL
Intervention: Quality of Life Inventory (QOLI)
Number of subjects: 0
Study: 15510875

Group type: EXPERIMENTAL
Intervention: Protect Liner F (PL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Panavia F (PF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DC core‐Light cured (DCL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DC core‐Chemically cured (DCC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Super‐EBA (SE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketac (KC)
Number of subjects: 100
Study: 11053502

Group type: EXPERIMENTAL
Intervention: Low-methionine intervention diet for 1 week followed by a control diet for 1 week (top quartile group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-methionine intervention diet for 1 week followed by a control diet for 1 week (bottom quartile group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control diet (for both groups)
Number of subjects: 52
Study: 9248984

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 200
Study: 8390288

Group type: EXPERIMENTAL
Intervention: In‐111‐labelled Mab F6 F(ab')2 fragments
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tc‐99m‐labelled BW 431/26 intact antibody
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal serum CEA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Abnormally elevated serum CEA
Number of subjects: 21
Study: 3621821

Group type: EXPERIMENTAL
Intervention: Conventional ionic medium (meglumine iothalamate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low osmolar medium (sodium meglumine ioxaglate)
Number of subjects: 0
Study: 29748010

Group type: EXPERIMENTAL
Intervention: Chemotherapy + pelareorep (4.5 × 10^10 TCID50, days 1-3 every 21 days)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Chemotherapy alone (pemetrexed [500 mg/m2, non-squamous] or docetaxel [75 mg/m2], day 1 every 21 days)
Number of subjects: 166
Study: 27240903

Group type: EXPERIMENTAL
Intervention: 4 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 6 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 6 or 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161
Study: 24966134

Group type: EXPERIMENTAL
Intervention: Intervention group (school-community program)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Intervention non-completers
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Intervention completers
Number of subjects: 614

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 614
Study: 22293092

Group type: EXPERIMENTAL
Intervention: Rehabilitation program targeting the opening of intervertebral foramen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 36
Study: 19941345

Group type: EXPERIMENTAL
Intervention: Combined Sensory Index (CSI)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: CSI of 2.5-4.6
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Median compound muscle action potential (CMAP) amplitude and median motor latency
Number of subjects: 272
Study: 18285606

Group type: EXPERIMENTAL
Intervention: Targeted anticancer agents (various agents, specific dosages and durations not provided)
Number of subjects: 89
Study: 15678039

Group type: COMPARATOR
Intervention: Peak creatine kinase MB level < 25 ng/mL
Number of subjects: 800

Group type: COMPARATOR
Intervention: Peak creatine kinase MB level ≥ 100 ng/mL
Number of subjects: 800
Study: 14654628

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: RSV-IGIV
Number of subjects: 0
Study: 10385364

Group type: EXPERIMENTAL
Intervention: Splenectomy with immunotherapy in patients with high IAP levels (>580 microg/ml)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Preservation of the spleen with immunotherapy in patients with lower IAP values
Number of subjects: 253
Study: 9038461

Group type: EXPERIMENTAL
Intervention: Jaw thrust as a clinical test for depth of anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loss of verbal contact
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol for loss of verbal contact
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol for loss of response to jaw thrust
Number of subjects: 60

Group type: COMPARATOR
Intervention: Jaw thrust vs loss of verbal contact
Number of subjects: 60
Study: 1633275

Group type: EXPERIMENTAL
Intervention: Training with the right hand
Number of subjects: 48

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 48
Study: 6175254

Group type: EXPERIMENTAL
Intervention: Sustained release pseudoephedrine (SUDAFED S.A.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31907388

Group type: EXPERIMENTAL
Intervention: Lower age of first sexual intercourse (AFS)
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Higher cognition genetic variants
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Lifestyle features
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Thrombotic conditions
Number of subjects: 10481
Study: 30787634

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone (T20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone (T40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 mg methylprednisolone (M20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone (M40)
Number of subjects: 80
Study: 28450312

Group type: EXPERIMENTAL
Intervention: MTX+pred
Number of subjects: 218

Group type: COMPARATOR
Intervention: MTX+plac
Number of subjects: 218
Study: 26573086

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study: 25205408

Group type: EXPERIMENTAL
Intervention: Levobupivacaine before trocar site incision and intraperitoneal levobupivacaine immediately after pneumoperitoneum (Group BS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intraperitoneal levobupivacaine before trocars were withdrawn and incisional levobupivacaine at the end of surgery (Group AS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 66
Study: 18222357

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study: 15198767

Group type: EXPERIMENTAL
Intervention: Needle excision of the transformation zone (NETZ)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Loop excision (LLETZ)
Number of subjects: 404
Study: 11878090

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (balneological care)
Number of subjects: 20
Study: 9160697

Group type: COMPARATOR
Intervention: CSP only
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CSP plus MP
Number of subjects: 104
Study: 7970954

Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group A, 6 units)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group B, 13 units)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group C, 25 units)
Number of subjects: 102
Study: 3313257

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 11563435

Group type: EXPERIMENTAL
Intervention: Medication treatment for pathologic gambling disorder (PGD) in geriatric patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nonpharmacologic treatment
Number of subjects: 73
Study: 30605260

Group type: EXPERIMENTAL
Intervention: Plazomicin 15 mg/kg
Number of subjects: 16
Study: 30248987

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (25 g of crude protein)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (25 g of crude protein)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insect protein isolate (25 g of crude protein)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 6
Study: 25965008

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) at the time of primary cutaneous tumor resection or at secondary wide local excision
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 57
Study: 24824991

Group type: EXPERIMENTAL
Intervention: Group treatment using the Lidcombe Program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Individual treatment using the Lidcombe Program
Number of subjects: 54
Study: 22258267

Group type: EXPERIMENTAL
Intervention: Oral liquid and perceived gastric liquid preloads
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Perceived gastric liquid preloads
Number of subjects: 52